Compare · MDLN vs TFX
MDLN vs TFX
Side-by-side comparison of Medline Inc. (MDLN) and Teleflex Incorporated (TFX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TFX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.52B, about 8.3x TFX ($6.23B).
- MDLN has been more active in the news (13 items in the past 4 weeks vs 6 for TFX).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Teleflex Incorporated
- Price
- -
- -
- Market cap
- $51.52B
- $6.23B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 13
- 6
- Recent ratings
- 25
- 25
Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Latest MDLN
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.
- SEC Form SCHEDULE 13G filed by Medline Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest TFX
- Amendment: SEC Form SCHEDULE 13G/A filed by Teleflex Incorporated
- Teleflex to Present at the Jefferies Global Healthcare Conference in London
- SEC Form 10-Q filed by Teleflex Incorporated
- Teleflex Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Teleflex Announces Quarterly Dividend
- Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook
- Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
- Teleflex Announces Third Quarter 2026 Earnings Conference Call Information
- Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
- Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology